MARKET

AVAI

AVAI

AVAI BIO
OTCMQB
0.093
-0.002
-2.42%
Closed 15:54 10/26 EDT
OPEN
0.100
PREV CLOSE
0.095
HIGH
0.105
LOW
0.093
VOLUME
18.70K
TURNOVER
1.82K
52 WEEK HIGH
0.800
52 WEEK LOW
0.090
MARKET CAP
14.27M
P/E (TTM)
-7.2992
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVAI last week (1019-1023)?
Weekly Report · 16h ago
Weekly Report: what happened at AVAI last week (1012-1016)?
Weekly Report · 10/19 09:15
Weekly Report: what happened at AVAI last week (1005-1009)?
Weekly Report · 10/12 09:16
Avaí Bio, JV Partner Austrianova Announce First Joint Steering Committee Meeting For Partnership With Ospedale San Raffaele Over Discussion On Initial Research Program To Mull Encapsulated Beta-Cell Replacement Approach For Insulin-Dependent Diabetes
Benzinga · 10/07 12:47
Weekly Report: what happened at AVAI last week (0928-1002)?
Weekly Report · 10/05 09:16
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
Barchart · 09/30 07:45
Weekly Report: what happened at AVAI last week (0921-0925)?
Weekly Report · 09/28 09:15
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
Barchart · 09/24 07:45
More
About AVAI
Avai Bio, Inc., formerly Avant Technologies, Inc., is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing cell-based therapies. The Company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an a-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. It has secured Joint Venture and Licensing Agreements to develop both cell lines. Its diabetes program is focused on developing an insulin-producing cell line, then encapsulating those cells inside using SGAustria's Cell-in-a-Box technology to create a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes. The Company is partnering with biotech firms, universities, scientists, and clinicians to uncover solutions for diverse healthcare challenges.

Webull offers Avai Bio Inc stock information, including OTCMQB: AVAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVAI stock methods without spending real money on the virtual paper trading platform.